Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ExoFlo Infusion for Mild-to-Moderate COVID-19
NCT05125562Phase 2Withdrawn
- Sponsor
- Direct Biologics
- Start
- Dec 2022
- Primary completion
- Mar 2023
- Modality
- Lipid-based Nanoparticles, Cell Therapies
01
Overview
Phase 2, randomised, double-blind trial of bone marrow mesenchymal stem cell derived extracellular vesicles in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Direct Biologics. Primary endpoint: Change in SARS-CoV-2 log viral load from baseline to Day 7. Planned start Dec 2022; status: withdrawn.
02
Drugs
bone marrow mesenchymal stem cell derived extracellular vesicles
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05125562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05125562.